Leila Ghazal, MA

Leila is the Clinical Research Coordinator for Usona Institute’s Multi-Center, Randomized, Double-Blind, Support-of-Concept Phase 2 Study of Single-Dose Psilocybin for Major Depressive Disorder. Leila has worked closely with Principal Investigator Stephen Ross MD, primarily on the Usona trial, as well as Dr. Ross’ NIDA-funded study investigating CBD administration in patients with chronic radicular pain on chronic opioid therapy. Leila also worked on the qualitative data of a phase I/II controlled trial administering psilocybin to religious professionals and briefly worked with Dr. Bogenschutz on his Psilocybin-Assisted Treatment of Alcohol Dependence and Effects of cannabidiol in alcohol use disorder studies.

Leila serves as a primary point of contact for participants on the Usona trial and manages the day-to-day study acivities including recruitment, scheduling, finances and regulatory, creating systems, streamlining study processes, increasing efficiency as well as tackling complex challenges and unanticipated events.

She graduated from the New School for Social Research in 2019 with a Masters in Clinical Psychology and a concentration in Mental Health and Substance Abuse Counseling.

Leila hopes to serve as a facilitator for one of the upcoming clinical trials. Her interest lies in the integration of spirituality into psychedelic therapy by supporting each individual in their own healing experience, particularly those who are in their final stages of life.